Table 1. Summary of the eligible trials in Bayesian network analysis.
| Study | Registered number | No. of patients | Stage | Radiotherapy | Induction chemotherapy | Concurrent Chemotherapy | Adjuvant chemotherapy |
|---|---|---|---|---|---|---|---|
| IC+CCRT vs CCRT | |||||||
| Fountzilas 2011 | ACTRN12609000730202 | 141 | AJCC 6th/IIb–IVb | 2DRT/3DRT | cisplatin, epirubicin and paclitaxel | cisplatin 40 mg/m2, qw | / |
| Tan 2015 | CDR0000657121 | 172 | UICC 1997/III-IVb | 2DRT/IMRT | gemcitabine, carboplatin and paclitaxel | cisplatin 40 mg/m2, qw | / |
| Frikha 2017 | NCT00828386 | 83 | -/T2b, T3, T4 and/or N1-N3, M0 | IMRT/non-IMRT | docetaxel, cisplatin and 5-fluorouracil | cisplatin 40 mg/m2, qw | / |
| Hong 2018 | NCT00201396 | 479 | AJCC 5th or UICC 1997/IVa–IVb | 3DRT/IMRT | mitomycin C, epirubicin, cisplatin and 5-fluorouracil | cisplatin 30 mg/m2, qw | / |
| Zhang 2019 | NCT01872962 | 480 | AJCC 7th/III–IVb | IMRT | gemcitabine and cisplatin | cisplatin 100 mg/m2, q3w | / |
| Sun 2016/Li 2019 | NCT01245959 | 480 | AJCC 7th or UICC 7th/III-IVb, except T3-4N0 | IMRT | docetaxel, cisplatin and 5-fluorouracil | cisplatin 100 mg/m2, q3w | / |
| Cao 2017/Yang 2019 | NCT00705627 | 476 | AJCC 6th or UICC 6th/III-IVb, except T3N0-1 | 2DRT/IMRT | cisplatin and 5-fluorouracil | cisplatin 80 mg/m2, q3w | / |
| CCRT vs CCRT+AC | |||||||
| Chen 2012/Chen 2017 | NCT00677118 | 508 | AJCC 6th/III-IVb, except T3-4N0 | 2DRT/3DRT/IMRT | / | cisplatin 40 mg/m2, qw | cisplatin and 5-fluorouracil |
| IC+CCRT vs CCRT+AC | |||||||
| Lee 2014 | NCT00379262 | 321 | AJCC 6th/III-IVb | 2DRT/3DRT/IMRT | cisplatin and 5-fluorouracil | cisplatin 100 mg/m2, q3w | cisplatin and 5-fluorouracil |
Abbreviation: IC, induction chemotherapy; CCRT, concurrent chemotherapy; AC, adjuvant chemotherapy; 2DRT, 2-dimensional radiotherapy; 3DRT, 3-dimensional radiotherapy; IMRT, intensity-modulated radiotherapy; AJCC, American Joint Committee on Cancer; UICC, Union for International Cancer Control.